Navigation Links
African parasite makes component of fat differently from all other organisms

Studying the parasite that causes African sleeping sickness, scientists at Johns Hopkins have discovered a previously unknown way of making fatty acids, a component of fat and the outer layer of all cells. The find unveils more about the biology of this hard-to-kill parasite and could lead to a target for designing new drugs to fight the illness that infects a half-million people and kills 50,000 a year worldwide.

Results of the study, in the Aug. 25 issue of Cell, "show that this is a completely new biochemical pathway for making fatty acids," says Soo Hee Lee, Ph.D., a postdoctoral fellow in the Department of Biological Chemistry at the Institute for Basic Biomedical Sciences at Hopkins. "It may be that the enzymes in the pathway could be good targets for designing drugs to treat sleeping sickness."

The single-celled trypanosome that causes African sleeping sickness, transmitted between humans and animals by bloodsucking tsetse flies, goes through several different stages in its life cycle. One such form is harbored by the insect and the other multiplies in a host's bloodstream.

There, the parasite avoids detection by the human immune system by replacing each of the 10 million proteins on its outer layer - known as the cell membrane - with different proteins that are not recognized by immune cells. These proteins are attached to the cell membrane by an anchor composed in part of a fatty acid only 14 units long - dubbed myristate -- whereas typically, in other organisms, these types of anchors contain longer fatty acids, generally 16 or 18 units long.

"For many years we thought the parasite had to get the myristate from its human host because we never could see any evidence that it could make the fatty acid itself," says Paul Englund, Ph.D., a professor of biological chemistry in the Institute of Basic Biomedical Sciences at Hopkins. "Several years ago we found that it does actually make myristate as well as other fatty acids, a nd now we found that it uses a biochemical pathway we never knew to look for."

They learned about this new fatty acid-making pathway by hunting the trypanosome genome for stretches of DNA known to be involved in fatty acid synthesis in other organisms, like animals and plants.

The researchers reasoned that knocking out the fatty acid-making genes would prevent the parasite from making myristate and other fatty acids.

But when one member of the research team, Jennifer Stephens, knocked out a single gene in the trypanosome known to make fatty acids in other organisms, there was no change in the parasite's ability to make myristate. Surprised, the researchers then examined the trypanosome genome more carefully and discovered enzymes that in other organisms are known to increase the size of a fatty acid molecule - dubbed elongases, for making fatty acids longer - but never have been shown to actually make a new fatty acid molecule.

Lee knocked out these elongases to see if the parasite might have difficulty making fatty acids. To the researchers' surprise, the parasites lacking elongases were unable to make the 14-unit myristate or other fatty acids.

"A novel feature of the elongase pathway is that it contains four different enzymes that take turns in elongating fatty acids," says Lee. "This modular pathway allows the parasite to control the size of the fatty acids it makes."

"It turns out that trypanosomes use an entirely unique mechanism of making fatty acids. No other organism ever studied uses elongases to make them," says Englund, suggesting that attacking biochemical pathways that make fatty acids could be a way to treat sleeping sickness. According to the researchers, the research community is extremely interested in developing drugs that target bacterial enzymes involved in fatty acid synthesis. An example of one is called isoniazid, which currently is used to treat tuberculosis.

"Trypanosomes c ause significant health problems in remote areas of Africa with poor health care," says Englund. "There is tremendous need for new drugs to cure these diseases."
'"/>

Source:Johns Hopkins Medical Institutions


Related biology news :

1. New push for public health, AIDS spending at African Union summit
2. South African Tribunal Asks For Damages Estimates in GSK AIDS Drug Case
3. Six million Africans face famine because of locusts, drought
4. Fungus-farming termites descend from an African rain forest Eve
5. Poaching, logging, and outbreaks of Ebola threaten central African gorillas and chimpanzees
6. Compound might defeat African sleeping sickness, clinical trial beginning this month
7. Crisis in African fish supplies looms, experts warn Africa leaders
8. New partnership to clear landmines for African Elephants
9. US/African project deciphers deadly parasite genome
10. Tropical Atlantic cooling and African deforestation correlate to drought, report scientists
11. Newly identified mechanism helps explain why people of African descent are more vulnerable to TB

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017  IBM ... Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, Home ... that will apply the power of IBM cognitive computing ... health centers. By analyzing data streaming from sensors in ... physical and environmental conditions, and obtain deeper learnings into ...
(Date:2/16/2017)... FRANCISCO , Feb. 16, 2017  Genos, ... today announced that it has received Laboratory Accreditation ... CAP Accreditation is presented to laboratories that meet ... who demonstrate scientifically rigorous processes. "Genos ... excellence in laboratory practices. We,re honored to be ...
(Date:2/13/2017)... 13, 2017  RSA Conference -- RSA, a Dell ... designed to enhance fraud detection and investigation across ... RSA Fraud & Risk Intelligence Suite. The new ... additional insights from internal and external sources as ... their customers from targeted cybercrime attacks. ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... 2017 Infectex Ltd., a Russian portfolio company of Maxwell Biotech ... SQ109 added to the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis ... ( USA ) and the US National Institutes of Health. ... ... Fund Logo ...
(Date:3/27/2017)... , March 27, 2017  Perthera,s Chief Bioinformatics ... Center, Subha Madhavan , Ph.D., will be speaking ... Summits Panels. On Monday, March 27, 2017, she will ... Data More Usable for Research and Care" (from 10:30 ... 28, 2017, she will be a participant in the ...
(Date:3/27/2017)... ... 27, 2017 , ... PMG Research is pleased to announce its ... The Conference Forum in Boston on April 3-4, 2017. The CTC conference focuses on ... outcomes and bring them closer to the patient. Clinical Trial Collaborations also will present ...
(Date:3/27/2017)... SAN DIEGO , March 27, 2017  Trovagene, ... announced that its Chief Executive Officer, Bill Welch ... on April 4, 2017 at 9:00 AM EDT at ... .  Bill Welch, and Chief Scientific Officer, ... meet with investors during the conference.   The ...
Breaking Biology Technology: